US 11,732,050 B2
Neutralizing human anti-CD27 antibodies
John Chen, San Diego, CA (US); Johan Fransson, Toronto (CA); Natalie Fursov, Harleysville, PA (US); Damon Hamel, San Diego, CA (US); Thomas Malia, Philadelphia, PA (US); Galina Obmolova, Phoenixville, PA (US); Tatiana Ort, Plymouth Meeting, PA (US); Michael Rycyzyn, Berwyn, PA (US); Michael Scully, Medford, NJ (US); Raymond Sweet, Bryn Mawr, PA (US); Alexey Teplyakov, Phoenixville, PA (US); John Wheeler, Devon, PA (US); and Juan Carlos Almagro, Brookline, MA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc, Horsham, PA (US)
Filed on May 19, 2020, as Appl. No. 16/878,209.
Application 16/878,209 is a division of application No. 16/382,645, filed on Apr. 12, 2019, granted, now 10,689,453.
Application 16/382,645 is a division of application No. 15/596,609, filed on May 16, 2017, granted, now 10,301,392.
Application 15/596,609 is a division of application No. 14/790,144, filed on Jul. 2, 2015, granted, now 9,683,046.
Application 14/790,144 is a division of application No. 13/835,518, filed on Mar. 15, 2013, granted, now 9,102,737.
Claims priority of provisional application 61/611,332, filed on Mar. 15, 2012.
Prior Publication US 2020/0277393 A1, Sep. 3, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 7 Claims
 
1. An isolated human anti-CD27 antibody or antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:
a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOS: 24-36, 153, and 155;
a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOs: 37-40 and 154; and
a CDRL3 amino acid sequence of SEQ ID NO: 41, and said heavy chain variable region comprising:
a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2;
a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOs: 3-22, 151, and 152; and
a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NOS: 23 and 162.